Azoospermia
Azoospermia is a severe form of male infertility characterized by the complete absence of sperm in the ejaculate. [1] This condition affects approximately 1% of all adult men [1] and male factors are understood to contribute to around half of all infertility cases globally. [1] The diagnosis and understanding of azoospermia have evolved over decades, with early studies focusing on its frequency and evaluation. [2]
Biological Basis
The biological basis of azoospermia can be broadly categorized into two main types: obstructive and non-obstructive. [1] Obstructive azoospermia occurs when sperm production is normal, but a blockage prevents sperm from being ejaculated. Non-obstructive azoospermia (NOA), conversely, is due to severely impaired spermatogenesis, the process of sperm development in the testes. [1] Known genetic causes for spermatogenic failure (SPGF) include karyotype abnormalities, such as Klinefelter syndrome, and microdeletions in the Y-chromosome AZF (Azoospermia Factor) locus. [3] However, the etiology of about 70% of SPGF cases remains unknown, suggesting that this idiopathic form of male infertility is a complex trait influenced by common genetic variants. [1] Recent research, including genome-wide association studies (GWAS), has identified variants within the HLA region as being associated with an increased risk for NOA. [4] Genes in this region, such as HLA-DRA and BTNL2, are involved in immune system regulation, suggesting that autoimmune inflammatory responses may contribute to testicular azoospermia. [4] Other genes implicated in NOA susceptibility include SOX5, PEX10, SIRPA-SIRPG, and PRMT6 [5] as well as genes like DMRT1 which are critical for testicular development. [6]
Clinical Relevance
Clinically, azoospermia is identified through semen analysis, which confirms the complete absence of spermatozoa. [7] A comprehensive evaluation of the azoospermic patient is crucial for determining the underlying cause and guiding treatment. [8] For individuals with NOA, assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI) combined with testicular sperm retrieval (TSR) may offer a pathway to biological fatherhood, though success rates can vary. [9] Genetic counseling and testing are often recommended to identify specific genetic causes, such as Y-chromosome microdeletions or chromosomal abnormalities. [10]
Social Importance
The social importance of azoospermia and male infertility is substantial, impacting individuals and couples on multiple levels. Infertility can lead to significant psychological distress, affecting relationships and overall quality of life. Given that male factors contribute significantly to infertility, addressing azoospermia is a critical component of reproductive health care. [1] Global studies highlight the widespread prevalence of infertility and its impact on disability-adjusted life-years, underscoring the need for continued research, improved diagnostic tools, and effective treatment strategies to support reproductive health worldwide. [11]
Methodological and Statistical Limitations
Genetic studies of azoospermia, while advancing understanding, face inherent methodological and statistical constraints. The current trans-ethnic meta-analysis, while pioneering in its scope, involved 2255 individuals with idiopathic spermatogenic failure (SPGF) and 3608 controls, a sample size that, while larger than previous single-ancestry studies, may still be insufficient to detect all genetic associations for a complex trait like azoospermia. [1] Indeed, certain meta-analyses, such as those combining Asian non-obstructive azoospermia (NOA) versus controls with European SPGF or NOA versus controls, did not yield genome-wide significant genetic associations, suggesting potential heterogeneity or insufficient power for specific comparisons. [1] Earlier genome-wide association studies (GWAS) on NOA in European populations with smaller cohorts (e.g., 40 cases and 80 controls) also failed to reach genome-wide significance, highlighting the challenge of replication and the potential for effect-size inflation in underpowered studies. [4]
Differences in sample composition across study cohorts can introduce bias and heterogeneity into the dataset. Although consistent diagnostic criteria were generally applied for inclusion, variations in the specific characteristics of the recruited populations, such as geographic origin or recruitment centers, could influence findings. [1] For instance, one study's NOA cases were primarily from Shandong province, with controls from Shanghai and Shandong, while a later stage expanded to other northern and central/southern Chinese provinces, indicating a focus on specific regional populations. [4] Such regional specificities, even within broad ethnic groups, can affect the generalizability of findings and necessitate careful consideration of population substructure in genetic analyses. [12]
Phenotypic Heterogeneity and Generalizability
A significant limitation in understanding azoospermia stems from variations in phenotype definition and the generalizability of findings across diverse populations. While trans-ethnic meta-analyses are valuable for boosting statistical power and refining causal variant identification by leveraging diverse linkage disequilibrium patterns, the specific populations included may not fully represent global genetic diversity. [1] The current research integrates data from European (Iberian Peninsula and Germany) and Han Chinese populations, which, while ethnically distinct, still represent only a fraction of worldwide ancestries. [1] This geographic and ethnic specificity means that genetic associations identified may not be universally applicable or might exhibit varying effect sizes in other underrepresented populations.
Furthermore, the level of phenotypic detail available for different cohorts introduces heterogeneity and impacts interpretation. The European SPGF cohort included detailed histological diagnoses, classifying patients into Sertoli cell-only (SCO), maturation arrest (MA), and hypospermatogenesis (HS), and also noted the success of testicular sperm retrieval. [1] In contrast, the analyzed Chinese cohort, while diagnosed with NOA, lacked this detailed histological phenotyping, which is an important limitation. [1] This disparity in diagnostic granularity can mask specific genetic associations or lead to imprecise conclusions when pooling data, as distinct underlying biological mechanisms might be grouped under a broader NOA diagnosis.
Unexplained Etiology and Environmental Influences
Despite significant efforts to uncover the genetic underpinnings of severe idiopathic male infertility, a complete understanding of its intricate molecular mechanisms remains elusive. A substantial proportion of the heritability for conditions like azoospermia is still unexplained, indicating considerable knowledge gaps that require further basic research before clinical applications can be fully realized. [1] This "missing heritability" suggests that current genetic models may not fully capture the complex interplay of genetic factors, gene-gene interactions, or epigenetic modifications contributing to the trait.
Environmental factors and gene-environment interactions are also critical, yet often under-explored, confounders in the etiology of azoospermia. Research suggests that changes in environmental exposures over decades may significantly influence the genetic architecture of severe spermatogenic failure. [13] However, the provided studies primarily focus on genetic variants and do not extensively detail specific environmental exposures or how they might interact with identified genetic predispositions. A comprehensive understanding of azoospermia will necessitate integrating environmental data with genetic insights to fully account for its complex, multifactorial nature.
Variants
The genetic landscape of azoospermia, particularly its nonobstructive form, involves a complex interplay of variants within genes governing immune responses, developmental processes, and cellular signaling. These variations can disrupt the intricate mechanisms of spermatogenesis, leading to the absence of sperm in the ejaculate.
The Major Histocompatibility Complex (MHC) region on chromosome 6 hosts several variants strongly implicated in nonobstructive azoospermia (NOA) due to their critical role in immune system regulation. The variant rs34915133, located between the HLA-DRB1 and HLA-DQA1 genes, is notably associated with NOA and a range of autoimmune conditions, including ulcerative colitis, systemic lupus erythematosus, and sarcoidosis. [4] These genes encode proteins essential for presenting antigens to T cells, thereby initiating immune responses. Functional analysis of rs349133 and its proxies indicates they influence promoter regions in various cell types and alter binding sites for proteins and transcription factors crucial for testicular function, suggesting a mechanism where immune dysregulation leads to testicular damage. [4] Similarly, rs7192 in the HLA-DRA gene, another MHC class II component, is also vital for antigen presentation by immune cells like B lymphocytes and macrophages, potentially contributing to immune-mediated testicular inflammation. [4] This highlights how genetic variations in immune-related genes can disrupt the delicate testicular microenvironment and lead to spermatogenic failure.
Another key variant influencing immune and inflammatory pathways is rs13206743, located near the IL17A gene. IL17A encodes Interleukin 17A, a cytokine that plays a significant role in inflammatory responses and immune system signaling. Elevated levels of IL-17, often produced by Th17 immune cells, are linked to testicular damage in men with azoospermia. [14] Specifically, IL17A has been shown to impair the integrity of the blood-testis barrier, a protective structure vital for spermatogenesis, and to induce inflammation within the testis. [15] The rs13206743 variant has also been associated with sex hormone-binding globulin levels and benign neoplasms of male genital organs, further underscoring its broad impact on male reproductive health. [4] These associations suggest that variations in IL17A can contribute to azoospermia by fostering an inflammatory environment that compromises testicular function.
Genetic variants in transcription factors and cell signaling genes also contribute significantly to the risk of azoospermia. The rs10842262 variant in the SOX5 gene is a pivotal genetic determinant in nonobstructive azoospermia (NOA), particularly in cases of Sertoli cell-only syndrome, and has been identified in various populations. [1] SOX5 is a transcription factor critical for developmental processes, including sex determination and differentiation, and is highly expressed in spermatocytes and round spermatids, indicating its role in sperm development. [4] Furthermore, polymorphisms in SIRPA, such as rs6080550, have been strongly associated with susceptibility to nonobstructive azoospermia. [5] SIRPA (Signal Regulatory Protein Alpha) is a cell surface protein involved in immune regulation, suggesting its variants might influence the immune environment within the testis. Finally, the rs2477686 variant, located within the PLCH2 gene, has also been linked to idiopathic male infertility risk. [1] PLCH2 (Phospholipase C Eta-2) plays a role in intracellular signaling pathways, which are fundamental for the proper development and function of germ cells.
Beyond protein-coding genes, variants in non-coding regions and pseudogenes also show associations with male infertility. The rs12097821 variant, located in a region encompassing the LINC01677 and MTATP6P14 genes, has been implicated in idiopathic male infertility risk. [1] LINC01677 is a long intergenic non-coding RNA, a type of RNA molecule known to regulate gene expression, and variations within it can impact its regulatory functions, potentially affecting genes involved in spermatogenesis. MTATP6P14 is a pseudogene related to mitochondrial ATP synthase, and while typically non-functional, pseudogenes can sometimes exert regulatory effects or serve as markers for nearby functional variants. Similarly, the rs142560854 variant is associated with the RPL23AP54 and RN7SKP159 pseudogenes, which are derived from ribosomal protein L23 and the 7SK small nuclear RNA, respectively. Although pseudogenes, their presence or variations can sometimes influence the expression of their functional counterparts or other genes, contributing to complex traits like azoospermia.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2477686 | PLCH2 | azoospermia Sertoli Cell-Only Syndrome |
| rs142560854 | RPL23AP54 - RN7SKP159 | azoospermia male infertility |
| rs12097821 | LINC01677 - MTATP6P14 | azoospermia Sertoli Cell-Only Syndrome |
| rs6080550 | CKAP2LP1 - SIRPA | azoospermia |
| rs10842262 | SOX5 | azoospermia Sertoli Cell-Only Syndrome |
| rs34915133 | HLA-DRB1 - HLA-DQA1 | azoospermia Sertoli Cell-Only Syndrome |
| rs13206743 | LINCMD1 - IL17A | azoospermia Sertoli Cell-Only Syndrome |
| rs7192 | HLA-DRA | azoospermia Henoch-Schoenlein purpura |
Definition and Diagnostic Criteria
Azoospermia is precisely defined as the complete absence of spermatozoa in the ejaculate, representing the most severe form of male infertility. [16] This condition affects approximately 1% of all adult men and is a significant contributor to male factor infertility, which accounts for about half of all infertility cases. [16] Operationally, diagnosis involves a thorough evaluation of the centrifuged semen pellet, where the absence of any detectable sperm confirms azoospermia. [4] Clinical and research criteria for defining unaffected control individuals typically adhere to World Health Organization (WHO) standards, requiring a sperm concentration greater than 20 million/ml, progressive sperm motility exceeding 40%, viability over 50%, and normal morphology for more than 30% of sperm heads and 65% of sperm tails. [4]
Classification and Subtypes
Azoospermia is broadly classified into two main categories: obstructive azoospermia and non-obstructive azoospermia (NOA). Obstructive azoospermia arises from an obstruction in the post-testicular tract, preventing sperm from reaching the ejaculate despite normal sperm production. In contrast, NOA is characterized by a complete absence of sperm in the ejaculate due to severely impaired spermatogenesis, a condition often termed spermatogenic failure (SPGF). [16] SPGF can also manifest as severe oligozoospermia (SO), where sperm counts are drastically reduced but not entirely absent. [16] The etiology of SPGF can be attributed to known genetic factors such as karyotype abnormalities (e.g., Klinefelter syndrome), microdeletions within the Y-chromosome AZF locus, and rare mutations in genes critical for spermatogenesis. [3] However, for a substantial proportion, around 70% of SPGF cases are considered idiopathic, with an unknown etiology, suggesting a complex genetic architecture involving common genetic variations. [16] Further classification of NOA can be achieved through testicular biopsy, which reveals distinct histological patterns, including Sertoli cell-only (SCO) syndrome, maturation arrest (MA), and hypospermatogenesis (HS). [16]
Terminology and Clinical Context
Key terminology in the field of male infertility includes "azoospermia" for the complete absence of sperm, and its primary subdivision into "obstructive azoospermia" and "non-obstructive azoospermia" (NOA). The term "spermatogenic failure" (SPGF) is often used interchangeably with NOA, emphasizing the underlying impairment in sperm production. "Severe oligozoospermia" (SO) describes a related condition of extremely low sperm count, falling short of complete absence. When the specific cause remains elusive, the term "idiopathic" is appended, as in "idiopathic SPGF" or "idiopathic NOA." Genetic nomenclature frequently references the AZF (Azoospermia Factor) locus on the Y chromosome, where microdeletions are a recognized cause of severe spermatogenic impairment. [3] Diagnostic approaches leverage standardized vocabularies and criteria, such as the World Health Organization's guidelines for semen analysis, to ensure consistency in clinical and research settings. [4] The ongoing investigation into the genetic landscape of NOA, including genome-wide association studies, continues to refine our understanding of its complex etiology and informs potential therapeutic strategies. [4]
Biological Background of Azoospermia
Azoospermia, defined as the complete absence of sperm in the ejaculate, represents the most severe form of male infertility. It affects approximately 1% of all adult men and contributes significantly to male factor infertility, which accounts for about half of all infertility cases. [1] The condition is broadly categorized into obstructive azoospermia, where sperm production is normal but blocked, and non-obstructive azoospermia (NOA), where the absence of sperm is due to severely impaired or failed spermatogenesis. [1] While some cases have known genetic causes, the etiology of a substantial portion, around 70% of spermatogenic failure (SPGF) cases, remains unknown, suggesting a complex genetic architecture involving common genetic variations. [1] Understanding the intricate biological mechanisms underlying spermatogenesis, its genetic regulation, and potential disruptions is crucial for unraveling the complexities of azoospermia.
Spermatogenesis and Testicular Microenvironment
Spermatogenesis, the highly organized process of sperm production, occurs within the seminiferous tubules of the testes and is critically dependent on the support of Sertoli cells. These somatic cells are fundamental for germ cell development, providing structural support, nutrients, and regulatory signals. [1] A key protective feature of the testicular microenvironment is the blood-testis barrier (BTB), formed by specialized tight junctions between adjacent Sertoli cells. This barrier separates the adluminal compartment, where meiosis and spermiogenesis occur, from the basal compartment, safeguarding developing germ cells from potentially harmful substances and immune surveillance. [17] The integrity of the BTB relies on crucial tight junction proteins such as occludin and ZO-1 (TJP1), which link transmembrane components to the actin cytoskeleton, thereby maintaining the barrier's structural and functional integrity. [18] Disruptions to this delicate balance, including impaired BTB permeability or loss of occludin expression, can lead to testicular dysfunction and contribute to spermatogenic failure. [4]
Genetic Determinants of Spermatogenic Failure
The genetic landscape of azoospermia is complex, ranging from gross chromosomal abnormalities to subtle single-nucleotide polymorphisms (SNPs). Well-established genetic causes include karyotype abnormalities, such as Klinefelter syndrome, and microdeletions within the Azoospermia Factor (AZF) locus on the Y chromosome, which are known to cause severe oligozoospermia or azoospermia. [3] Beyond these major alterations, rare mutations in genes essential for spermatogenesis have been identified. However, the majority of idiopathic non-obstructive azoospermia (NOA) cases are considered complex traits influenced by common genetic variants. [1]
Recent genome-wide association studies (GWAS) have begun to uncover additional genetic susceptibility loci. For instance, variants within the Human Leukocyte Antigen (HLA) region have been strongly associated with an increased risk for NOA. [4] Other genes implicated through polymorphism studies include SOX5, PEX10, SIRPA-SIRPG, and PRMT6, suggesting their roles in various aspects of testicular function and spermatogenesis. [5] For example, SOX5 is involved in gonadal development and histone modification. [4] Furthermore, the transcription factor DMRT1 (Doublesex and mab-3 related transcription factor 1) is critical for preventing female reprogramming in the postnatal mammalian testis and plays a fundamental role in vertebrate gametogenesis; rare regulatory variants in DMRT1 have been linked to severe spermatogenic failure, and its repression can induce testicular dysgenesis. [6] These genetic insights highlight the diverse molecular pathways that can be disrupted, leading to the failure of sperm production.
Immune System Involvement in Azoospermia Pathogenesis
Emerging evidence strongly suggests an immune-mediated component in the pathogenesis of certain forms of spermatogenic failure, particularly Sertoli cell-only syndrome (SCO). [1] The association of NOA with variants in the HLA (Major Histocompatibility Complex) region underscores this immune link. [4] The HLA region encodes proteins vital for immune recognition, such as HLA-DRA, a component of MHC class II molecules that presents peptides to T cells on antigen-presenting cells. [4] Another protein encoded in this region, BTNL2, is an immunoglobulin superfamily membrane protein involved in regulating T-cell activation. [4] Variations in these genes may alter immune responses to antigens within the testicular microenvironment, potentially triggering autoimmune inflammatory reactions that damage the testes and impair spermatogenesis. [4]
Inflammation is a recurring theme in spermatogenic failure, with global gene expression profiling of azoospermia patients revealing the involvement of inflammation-related genes. [19] An immunodeviation towards a Th17 immune response has been associated with testicular damage in azoospermic men. [14] Key cytokines, such as IL17A, produced by Th17 cells, have been shown to impair the integrity of the blood-testis barrier and induce testicular inflammation, further highlighting how immune dysregulation can directly compromise the delicate environment required for sperm development. [4] This immune-mediated testicular damage can lead to the severe impairment of spermatogenesis characteristic of NOA.
Pathophysiological Processes Leading to Non-Obstructive Azoospermia
Non-obstructive azoospermia (NOA) arises from fundamental disruptions in the physiological processes of spermatogenesis, resulting in a complete absence of sperm. This can manifest as various forms of spermatogenic failure, including maturation arrest, hypospermatogenesis, or Sertoli cell-only (SCO) syndrome, where only Sertoli cells are present in the seminiferous tubules, indicating a complete absence of germ cells. [20] The underlying mechanisms often involve developmental defects, homeostatic disruptions, or pathological processes that impair the proliferation, differentiation, and maturation of germ cells.
Inflammation within the testicular tissue, potentially triggered by genetic predispositions or environmental factors, plays a significant role in compromising spermatogenic function. [19] The integrity of the blood-testis barrier (BTB) is paramount for maintaining the immune-privileged status of the testes and protecting developing germ cells. When this barrier is compromised, as seen with impaired permeability and loss of occludin expression in autoimmune orchitis, the testicular environment becomes vulnerable to immune attack, further disrupting spermatogenesis. [4] These pathophysiological events, whether primary defects in germ cell development or secondary damage from immune responses, collectively lead to the severe impairment of sperm production that defines NOA.
Immune-Mediated Pathogenesis and Inflammatory Signaling
Azoospermia, particularly its non-obstructive forms, is significantly influenced by immune system dysregulation and inflammatory signaling within the testicular microenvironment. Genetic variants within the Human Leukocyte Antigen (HLA) region are strongly associated with an increased risk for non-obstructive azoospermia, suggesting a role for immune-mediated mechanisms. [4] The HLA complex, including genes like HLA-DRA, is crucial for presenting peptides to T cells, while BTNL2 regulates T cell activation . Patients undergoing genetic screening for azoospermia must provide fully informed consent, understanding the potential implications of results, including the discovery of predispositions to other conditions or information that may impact family members. Furthermore, the sensitive nature of genetic data necessitates robust privacy protections to prevent genetic discrimination in areas such as employment or insurance, ensuring individuals are not unfairly penalized for their genetic profile related to infertility. These genetic findings profoundly influence reproductive choices, guiding decisions about assisted reproductive technologies like intracytoplasmic sperm injection (ICSI), sperm donation, or adoption, and requiring comprehensive genetic counseling to support individuals and couples in making autonomous and well-informed decisions.
Addressing Social Stigma and Health Equity
Azoospermia, as a severe form of male infertility, can carry considerable social stigma in many cultures, impacting an individual's self-esteem and social standing. [1] This stigma, combined with socioeconomic factors, contributes to significant health disparities in access to diagnosis and treatment. Individuals from lower socioeconomic backgrounds or those in underserved regions may face barriers to obtaining specialized care, genetic testing, and assisted reproductive technologies, exacerbating existing inequalities in healthcare access. Cultural considerations also play a crucial role, as societal norms and beliefs about family, reproduction, and masculinity can influence how infertility is perceived, discussed, and treated, highlighting the need for culturally sensitive approaches to care and support.
Governance of Genetic Research and Clinical Practice
The rapid advancements in genetic research, particularly through trans-ethnic genome-wide association studies (GWAS) involving diverse populations from Europe and Asia, necessitate stringent policy and regulatory frameworks. [1] Robust genetic testing regulations and data protection measures are essential to safeguard the privacy of participants, especially concerning individual-level genotype data, which legal restrictions in regions like Europe and China prevent from being publicly available. [1] Upholding research ethics is paramount, ensuring equitable participant recruitment, transparent informed consent processes, and responsible data sharing practices that balance scientific advancement with individual rights. These ethical considerations must also inform the development of clinical guidelines, ensuring that the diagnosis, counseling, and treatment of azoospermia are conducted with the highest standards of care and respect for patient autonomy and well-being.
Frequently Asked Questions About Azoospermia
These questions address the most important and specific aspects of azoospermia based on current genetic research.
1. If I have azoospermia, will my son have it?
It depends on the underlying cause of your azoospermia. If your condition is due to Y-chromosome microdeletions or certain chromosomal abnormalities like Klinefelter syndrome, there's a risk of passing on genetic factors. For Y-chromosome microdeletions, this specifically affects male offspring if you use assisted reproductive technologies. However, many cases are idiopathic, meaning the specific genetic cause isn't fully understood and inheritance might be less direct. Genetic counseling can help assess your specific risk.
2. Could my immune system be why I can't have kids?
Yes, it's a possibility. Recent research has linked variants in the HLA region, which contains genes like HLA-DRA and BTNL2 involved in immune system regulation, to an increased risk for non-obstructive azoospermia. This suggests that autoimmune inflammatory responses might contribute to problems with sperm development in your testes. It's an area of ongoing study that highlights an unexpected connection.
3. I'm healthy; why am I still having fertility issues?
Unfortunately, male infertility, including azoospermia, often has complex causes beyond general health habits. For about 70% of cases where sperm production is severely impaired (non-obstructive azoospermia), the exact reason is unknown, even in healthy individuals. This "idiopathic" form is considered a complex trait influenced by many common genetic variants you carry, rather than just lifestyle choices. Genes critical for testicular development or sperm production can be subtly altered without showing other health issues.
4. Is getting a genetic test really worth it for my fertility?
Yes, genetic testing can be very valuable. It's often recommended to identify specific underlying causes, such as Y-chromosome microdeletions or chromosomal abnormalities, which are known genetic factors for azoospermia. Knowing the genetic cause can help guide your treatment options, inform the potential success rates for assisted reproductive technologies, and provide important information for family planning decisions.
5. Why do some men produce sperm but it never comes out?
This is known as obstructive azoospermia. In these cases, sperm production in the testes is normal, but a physical blockage somewhere in the reproductive tract prevents the sperm from being ejaculated. This blockage isn't typically due to genetic issues affecting sperm production itself, but rather structural problems that might be congenital or acquired. It's a distinct condition from non-obstructive azoospermia, where the problem lies with sperm development.
6. Can I still have biological children with this condition?
For many men with non-obstructive azoospermia, biological fatherhood is possible. Assisted reproductive technologies (ART), such as intracytoplasmic sperm injection (ICSI) combined with testicular sperm retrieval (TSR), can be used to extract sperm directly from the testes. While success rates can vary depending on the specific cause and individual factors, these methods offer a pathway to having your own biological children.
7. Is it normal to feel so stressed about my infertility?
Absolutely, it's very normal and common to experience significant psychological distress. Infertility, including azoospermia, affects individuals and couples profoundly, impacting relationships and overall quality of life. The challenges of diagnosis, treatment, and the uncertainty of outcomes can be emotionally taxing. Seeking support from healthcare professionals or support groups is important for your well-being.
8. Did anything in my childhood make me infertile?
It's unlikely that specific events in your childhood directly caused your azoospermia, especially if it has a genetic basis. Many genetic causes, such as chromosomal abnormalities or mutations in genes critical for testicular development like DMRT1, originate early in fetal development or are inherited. These issues affect the formation or function of the reproductive system from the start, rather than being triggered by later childhood experiences or environmental factors.
9. Why is having kids easy for others, but hard for me?
Fertility varies greatly among individuals due to a complex interplay of factors, many of which are genetic. Azoospermia affects about 1% of adult men, and for a large portion of these cases, the cause is genetic, even if it's not fully identified. You might carry common genetic variants or specific genetic conditions that impact sperm production or transport, making conception more challenging compared to others who don't have these particular genetic predispositions.
10. Can I do anything to prevent this from happening to my body?
Unfortunately, for genetically-driven forms of azoospermia, there isn't a known way to prevent the condition from developing. Many cases stem from genetic factors, such as chromosomal abnormalities, Y-chromosome microdeletions, or variants in genes affecting sperm development, which are present from birth. While maintaining a healthy lifestyle is always beneficial for overall health, it generally doesn't alter these underlying genetic predispositions that cause azoospermia.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Gonzalez-Munoz, S. et al. "Trans-ethnic GWAS meta-analysis of idiopathic spermatogenic failure highlights the immune-mediated nature of Sertoli cell-only syndrome." Commun Biol, 2025.
[2] Willott, G.M. "Frequency of azoospermia." Forensic Sci. Int., vol. 20, 1982, pp. 9–10.
[3] Reijo, R., et al. "Severe oligozoospermia resulting from deletions of azoospermia factor gene on Y chromosome." Lancet, vol. 347, 1996, pp. 1290–.
[4] Zhao, H. et al. "A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia." Am J Hum Genet, vol. 90, 2012, pp. 900–906.
[5] Gu, X. et al. "PEX10, SIRPA-SIRPG, and SOX5 gene polymorphisms are strongly associated with nonobstructive azoospermia susceptibility." J. Assist. Reprod. Genet., vol. 36, 2019, pp. 759–768.
[6] Matson, C. K., et al. "DMRT1 prevents female reprogramming in the postnatal mammalian testis." Nature, vol. 476, no. 7358, 2011, pp. 101–104.
[7] Cooper, T.G., et al. "World Health Organization reference values for human semen characteristics." Hum. Reprod. Update, vol. 16, 2010, pp. 231–245.
[8] Jarow, J.P., et al. "Evaluation of the azoospermic patient." J. Urol., vol. 142, 1989, pp. 62–65.
[9] Corona, G., et al. "Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis." Hum. Reprod. Update, vol. 25, 2019, pp. 733–757.
[10] Dohle, G.R., et al. "Genetic risk factors in infertile men with severe oligozoospermia and azoospermia." Hum. Reprod., vol. 17, 2002, pp. 13–16.
[11] Sun, H., et al. "Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017." Aging, vol. 11, 2019, pp. 10952–10991.
[12] Xu, S., et al. "Genomic dissection of population substructure of Han Chinese and its implication in association studies." American Journal of Human Genetics, vol. 85, no. 5, 2009, pp. 762–774.
[13] Cervan-Martin, M., et al. "Changes in environmental exposures over decades may influence the genetic architecture of severe spermatogenic failure." Human Reproduction, vol. 39, 2024, pp. 612–622.
[14] Duan, Y. G. et al. "Immunodeviation towards a Th17 immune response associated with testicular damage in azoospermic men." Int. J. Androl., vol. 34, 2011, pp. e536–e545.
[15] Perez, C. V. et al. "IL17A impairs blood-testis barrier integrity and induces testicular inflammation." Cell Tissue Res., vol. 358, 2014, pp. 885–898.
[16] González-Muñoz, Sara, et al. "Trans-ethnic GWAS meta-analysis of idiopathic spermatogenic failure highlights the immune-mediated nature of Sertoli cell-only syndrome." Communications Biology, vol. 8, 2025, p. 571.
[17] Mruk, D. D., and C. Y. Cheng. "The Mammalian blood-testis barrier: its biology and regulation." Endocr. Rev., vol. 36, no. 5, 2015, pp. 564–591.
[18] Fanning, A. S., et al. "The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton." J. Biol. Chem., vol. 273, no. 45, 1998, pp. 29745–29753.
[19] Spiess, A.N., et al. "Global gene expression profiling of testicular biopsies from azoospermia patients." Journal of Andrology, vol. 28, no. 4, 2007, pp. 590–598.
[20] Ghanami Gashti, N., et al. "Sertoli cell-only syndrome: etiology and clinical management." Journal of Assisted Reproduction and Genetics, vol. 38, no. 3, 2021, pp. 559–572.